ABVC BioPharma

Moat assessment by component. Intangible assets: limited early‑stage patent estate around botanical extracts (for example ABV‑1505) and know‑how; however, botanical IP is typically narrower and easier to design around than NCEs.

Score 25/100. Switching costs: none until products are approved and adopted; today there is no installed base or clinical guideline entrenchment. Score 0/100. Network effects: none. Score 0/100. Cost advantages: absent; as a small sponsor with a modest in‑house CDMO (BioKey), there is no cost leadership versus larger peers.

Score 10/100. Efficient scale: niche ocular device (Vitargus) could face capacity or regulatory barriers if proven, but evidence is early; competitive response from incumbent tamponade materials is expected.

Score 10/100. Overall moat score is a weighted blend emphasizing switching costs and network effects (70%) and intangibles/cost/scale (30%), which yields approximately 15/100. Key erosion risks: lack of clinical differentiation, limited IP breadth, and capital constraints delaying trials.